

12 October 2021

Triple-Negative Breast Cancer pharma

1 – In the past three months, how many patients were treated for Triple-Negative Breast Cancer with the following:

- a) Anthracycline (eg doxorubicin) as a single agent : 0
- b) Atezolizumab + nab-paclitaxel or paclitaxel : 2
- c) Capecitabine as a single agent : 4
- d) Eribulin as a single agent : 0
- e) Eribulin + other chemotherapy :0
- f) PARP inhibitor (eg Olaparib) : 0
- g) Platinum (eg carboplatin, cisplatin) as a single agent : 3
- h) Taxane (eg docetaxel, paclitaxel, nab-paclitaxel) as a single agent : 1
- i) Other single agent chemotherapy : 0
- j) Other chemotherapy combination : 12
- k) Other immunotherapy containing regimen : 0
- l) Other active systemic anti-cancer therapy :0

2 – How many of these Triple-Negative Breast Cancer patients treated in the last three months received treatment that was:

- a) Privately funded : 0
- b) Part of clinical trial : 0
- c) Part of an early access scheme : 0